← All trials
NCT02861586
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Aug 1, 2017
- Completion date
- Aug 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 320
- Arms / groups
- 8 / —
- Source
- AACT · pre-existing
Sponsors
- Themis Bioscience GmbHLead sponsor
- Envigo Pharma Consulting LimitedCollaborator
- University of ViennaOverall official - principal investigator
- Medical University of GrazOverall official - principal investigator
- SRI InternationalCollaborator
- Biofabri, S.LCollaborator
- University of ViennaCollaborator
- Assign Clinical Research GmbHCollaborator
- ABF Pharmaceutical Services GmbHCollaborator
- Batavia BiosciencesCollaborator
- University of RostockOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.